Cargando…
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
BACKGROUND AND AIMS: Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, management and outcome. METHODS: The Epidemiological Str...
Autores principales: | Sirieix, Junien, Fraisse, Julien, Mathoulin-Pelissier, Simone, Leheurteur, Marianne, Vanlemmens, Laurence, Jouannaud, Christelle, Diéras, Véronique, Lévy, Christelle, Ung, Mony, Mouret-Reynier, Marie-Ange, Petit, Thierry, Coudert, Bruno, Brain, Etienne, Pistilli, Barbara, Ferrero, Jean-Marc, Goncalves, Anthony, Uwer, Lionel, Patsouris, Anne, Tredan, Olivier, Courtinard, Coralie, Gourgou, Sophie, Frénel, Jean-Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768846/ https://www.ncbi.nlm.nih.gov/pubmed/33488779 http://dx.doi.org/10.1177/1758835920980548 |
Ejemplares similares
-
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023) -
Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021) -
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022) -
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020) -
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)